Multiple Myeloma: key endpoint results by drug

The key endpoints of Multiple Myeloma trials, with each approved or late-stage drug's result from its own trial: the lead dose against placebo (or the trial's active comparator), the week, and the arm size. These are the same rows as the drug comparison, for every drug at once. To set chosen drugs side by side, with every shared endpoint, use the comparison. The drug list and pipeline are on the Multiple Myeloma page.

PFS, median

PFS, median in Multiple Myeloma: 17 drugs, each from its own trial
DrugResultControlDifferenceDose · week · nTrial
Belantamab mafodotin36.613.4 (Daratumumab)—n 243NCT04246047 Phase 3, primary
Bortezomib11.27.1 (BTZ+LD-DEX)—n 281NCT01734928 Phase 3, primary
Carfilzomib26.317.6 (Lenalidomide and Dexamethasone (Rd))—n 396NCT01080391 Phase 3, primary
Elotuzumab19.414.8 (Lenalidomide + Dexamethasone)—n 321NCT01239797 Phase 3, primary
Isatuximab11.56.5 (Pomalidomide + Dexamethasone)—n 154NCT02990338 Phase 3, primary
Ixazomib20.614.7+5.9n 360NCT01564537 Phase 3, primary
Lenalidomide35.321.8+13.5n 351NCT01850524 Phase 3, primary
Nirogacestat3.59.6 (Belantamab Mafodotin)—0.95mg/kg Q3W + Nirogacestat · n 34NCT07084896 Phase 1/2, secondary
Panobinostat12.08.8+3.2n 387NCT01023308 Phase 3, primary
Plitidepsin2.61.7 (Dexamethasone)—n 171NCT01102426 Phase 3, primary
Pomalidomide3.61.9 (Dexamethasone)—n 302NCT01311687 Phase 3, primary
Selinexor13.99.5 (Bortezomib + Dexamethasone)—n 195NCT03110562 Phase 3, primary
Daratumumab46.7b——n 444NCT02541383 Phase 3, primary
Elranatamab8b——1000 mcg/kg SC · n 6NCT03269136 Phase 1, secondary
Ibrutinib8.5b——n 74NCT02902965 Phase 2, primary
Idecabtagene vicleucel8.9b——n 137NCT03361748 Phase 2, secondary
Thalidomide46.7b——n 444NCT02541383 Phase 3, primary

Drugs checked with no result here: 32 not reported, 31 trial running, 2 not posted.

OS, median

OS, median in Multiple Myeloma: 16 drugs, each from its own trial
DrugResultControlDifferenceDose · week · nTrial
Belantamab mafodotin2422.9 (Pomalidomide Plus Dexamethasone)—n 218NCT04162210 Phase 3, secondary
Bortezomib83.053.6 (Velcade, Melphalan and Prednisone)—n 350NCT02195479 Phase 3, secondary
Carfilzomib10.210+0.2n 157NCT01302392 Phase 3, primary
Daratumumab67.651.8 (Lenalidomide, Low-dose Dexamethasone)—n 153NCT02076009 Phase 3, secondary
Elotuzumab48.339.6 (Lenalidomide + Dexamethasone)—n 321NCT01239797 Phase 3, secondary
Isatuximab24.617.7 (Pomalidomide + Dexamethasone)—n 154NCT02990338 Phase 3, secondary
Ixazomib53.651.6+2n 360NCT01564537 Phase 3, secondary
Lenalidomide39.331.5+7.8n 177NCT00056160 Phase 3, secondary
Panobinostat40.335.8+4.5n 387NCT01023308 Phase 3, secondary
Plitidepsin11.68.9 (Dexamethasone)—n 171NCT01102426 Phase 3, secondary
Pomalidomide12.58.1 (Dexamethasone)—n 302NCT01311687 Phase 3, secondary
Selinexor36.732.8 (Bortezomib + Dexamethasone)—n 195NCT03110562 Phase 3, secondary
Ciltacabtagene autoleucel27.0b——n 8NCT03548207 Phase 1/2, secondary
Elranatamab32.9b——600 mcg/kg SC · n 6NCT03269136 Phase 1, secondary
Idecabtagene vicleucel28.3b——n 137NCT03361748 Phase 2, secondary
Thalidomide49.8b——n 168NCT00507416 Phase 3, secondary

Drugs checked with no result here: 34 not reported, 30 trial running, 2 not posted.

ORR

ORR in Multiple Myeloma: 20 drugs, each from its own trial
DrugResultControlDifferenceDose · week · nTrial
Belantamab mafodotin41%36% (Pomalidomide Plus Dexamethasone)—n 218NCT04162210 Phase 3, secondary
Bortezomib90.9%73.9% (Velcade, Melphalan and Prednisone)—n 350NCT02195479 Phase 3, secondary
Daratumumab43.3%39.4% (Daratumumab IV)—n 263NCT03277105 Phase 3, primary
Elotuzumab78.5%65.5% (Lenalidomide + Dexamethasone)—n 321NCT01239797 Phase 3, primary
Isatuximab60.4%35.3% (Pomalidomide + Dexamethasone)—n 154NCT02990338 Phase 3, secondary
Ixazomib78.3%71.5%+6.8n 360NCT01564537 Phase 3, secondary
Lenalidomide78.5%65.5% (Lenalidomide + Dexamethasone)—n 321NCT01239797 Phase 3, primary
Nirogacestat29%38% (Belantamab Mafodotin)—0.95mg/kg Q3W + Nirogacestat · n 34NCT07084896 Phase 1/2, primary
Plitidepsin22.8%3.6% (Dexamethasone)—n 171NCT01102426 Phase 3, secondary
Selinexor76.4%62.3% (Bortezomib + Dexamethasone)—n 195NCT03110562 Phase 3, secondary
Carfilzomib82.5%b——20/56 mg/m^2 once weekly · n 228NCT03859427 Phase 3, primary
Ciltacabtagene autoleucel97.1%b——n 68NCT03548207 Phase 1/2, primary
Elranatamab53.3%b——n 30NCT05228470 Phase 2, primary
Ibrutinib56.8%b——n 74NCT02902965 Phase 2, secondary
Idecabtagene vicleucel74.5%b——n 137NCT03361748 Phase 2, primary
melphalan hydrochloride (Evomela)95%ab——wk 14.2857142857NCT01660633 Phase 2, primary
Mezagitamab47%b——600 mg · n 19NCT03439280 Phase 1/2, secondary
Panobinostat62.2%b——20 mg TIW · wk 24 · n 82NCT02654990 Phase 2, primary
Pomalidomide23%b——n 74NCT01324947 Phase 3, primary
Thalidomide73%b——n 147NCT00507416 Phase 3, secondary

Drugs checked with no result here: 30 not reported, 30 trial running, 2 not posted.

VGPR or better

VGPR or better in Multiple Myeloma: 11 drugs, each from its own trial
DrugResultControlDifferenceDose · week · nTrial
Bortezomib71.1%49.7% (Velcade, Melphalan and Prednisone)—n 350NCT02195479 Phase 3, secondary
Carfilzomib72.6%56.1% (Carfilzomib + Dexamethasone)—n 179NCT03275285 Phase 3, secondary
Daratumumab75.8%44.2% (Lenalidomide, Low-dose Dexamethasone)—n 281NCT02076009 Phase 3, secondary
Isatuximab31.8%8.5% (Pomalidomide + Dexamethasone)—n 154NCT02990338 Phase 3, secondary
Ixazomib48.1%39%+9.1n 360NCT01564537 Phase 3, secondary
Lenalidomide75.8%44.2% (Lenalidomide, Low-dose Dexamethasone)—n 281NCT02076009 Phase 3, secondary
Pomalidomide31.8%8.5% (Pomalidomide + Dexamethasone)—n 154NCT02990338 Phase 3, secondary
Selinexor44.6%32.4% (Bortezomib + Dexamethasone)—n 195NCT03110562 Phase 3, secondary
Belantamab mafodotin25%b——2.5 mg/kg Q3W · n 40NCT05064358 Phase 2, secondary
Ciltacabtagene autoleucel96.6%b——n 29NCT03548207 Phase 1/2, secondary
Thalidomide37%b——n 147NCT00507416 Phase 3, secondary

Drugs checked with no result here: 36 not reported, 31 trial running, 4 not posted.

MRD negativity

MRD negativity in Multiple Myeloma: 7 drugs, each from its own trial
DrugResultControlDifferenceDose · week · nTrial
Bortezomib53.3%35.4% (Bortezomib-lenalidomide-dexamethasone (VRd))—n 197NCT03652064 Phase 3, primary
Carfilzomib18.3%5.2% (Carfilzomib and Dexamethasone)—wk 52 · n 312NCT03158688 Phase 3, secondary
Daratumumab53.3%35.4% (Bortezomib-lenalidomide-dexamethasone (VRd))—n 197NCT03652064 Phase 3, primary
Ixazomib59%50%+9wk 72 · n 335NCT01850524 Phase 3, secondary
Lenalidomide53.3%35.4% (Bortezomib-lenalidomide-dexamethasone (VRd))—n 197NCT03652064 Phase 3, primary
Ciltacabtagene autoleucel100%b——n 18NCT03548207 Phase 1/2, secondary
Selinexor33.3%b——wk 12 · n 3NCT02780609 Phase 1/2, secondary

Drugs checked with no result here: 36 not reported, 32 trial running, 7 not posted.

  1. a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
  2. b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
  3. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  4. Rows are in drug-name order, not ranked. Difference is the lead arm minus placebo, in the endpoint's unit. 82 approved or late-stage drugs with a featured trial in Multiple Myeloma were checked; results come from ClinicalTrials.gov posted results unless marked. Updated 2026-11-20. How results are chosen: methodology.